Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gap junction protein delta-4 (GJD4) is a member of the connexin family of proteins that assemble to form gap junction channels, which create direct cytoplasmic connections between adjacent cells. Each gap junction channel is composed of two hemichannels (connexons), each made up of six connexin subunits such as GJD4. Through these channels, small molecules and ions (up to ~1 kDa) can diffuse, enabling the exchange of nutrients, metabolites, and signaling molecules between cells. GJD4 likely plays a role in modulating intercellular communication critical for functions like auditory signaling and may be involved in other physiological processes where gap junctions are essential. Deficiencies or mutations in connexin genes are known causes of diseases such as deafness and neuropathies, and while some disease associations exist for GJD4, functional and clinical relevance are still being elucidated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gap junction protein delta-4 (GJD4).